Boundless Bio, Inc. (BOLD) - Form 8-K Summary
Business Context and Reporting Period
Boundless Bio, Inc., a Delaware corporation, filed this Current Report on Form 8-K on May 8, 2026. The filing serves to announce the Company's financial results for the quarter ended March 31, 2026, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is incorporated by reference but not included in the text of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
This 8-K does not include specific guidance, management commentary, risk factors, or details on unusual items. The document explicitly states that the information in the press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless specifically stated by the Company.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific Q1 2026 financial figures.
- Verify the Company's cash runway and burn rate, as these are critical for pre-revenue biotech firms but are not listed in this summary.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.